The Administrative Core (Core A) will be managed by John Van den Anker, Program Director, and Edward Connor, Co-Program Director. Dr. Van den Anker is the Vice Chair of Pediatrics for Experimental Therapeutics at Children's National Medical Center (CNMC) and brings expertise in the management of programs such as the Pediatric Pharmacology Research Unit, and has extensive clinical and research expertise in several areas of developmental and pediatric pharmacology. He also serves as PI of Project 1 (Determine the time course of urine biomarkers for morpholino anti-sense oligonucleotides accumulation in renal epithelial cells). Dr. Connor is the Director of the Office of Innovation Development and Investigational Therapeutics and brings extensive expertise in pediatric drug development, clinical trials, clinical/translational research, and executive research management/administration and also serves as co-l of Project 1. The Co-Directors have complementary capabilities that will allow them to effectively direct the Administrative Core. This Core has two specific aims.
In Specific Aim 1, fiscal management of all Projects and Cores, oversight of balancing of Core resources, convening of the Internal Steering Committee as well as annual meetings of the External Advisory Board, and solicitation and processing of Pilot Project applications will be the responsibility of Dr. Van den Anker and his administrative team.
In Specific Aim 2, monthly conference calls of key personnel on all Projects and Cores, monitoring of research progress on each Project and Core, including timely achievement of milestones, oversight of annual scientific reports, and oversight and monitoring of human subjects and regulatory compliance will be the responsibility of Dr. Connor. Finally, both Drs. Van den Anker and Connor are tightly integrated into the CTSA efforts and this very active involvement of the CTSA within the RPDP investigations will ensure synergism with this nationally-based clinical and translational research effort.

National Institute of Health (NIH)
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZHD1-DSR-A)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Children's Research Institute
United States
Zip Code
Allegaert, Karel; Fanos, Vassilios; van den Anker, Johannes N et al. (2014) Perinatal pharmacology. Biomed Res Int 2014:101620
Tatem, Kathleen S; Quinn, James L; Phadke, Aditi et al. (2014) Behavioral and locomotor measurements using an open field activity monitoring system for skeletal muscle diseases. J Vis Exp :51785
Ward, Robert M; Allegaert, Karel; de Groot, Ronald et al. (2014) Commentary: Continuous infusion of vancomycin in neonates: to use or not to use remains the question. Pediatr Infect Dis J 33:606-7
van den Anker, Johannes N (2014) How to optimize the evaluation and use of antibiotics in neonates. Early Hum Dev 90 Suppl 1:S10-2
Uaesoontrachoon, Kitipong; Quinn, James L; Tatem, Kathleen S et al. (2014) Long-term treatment with naproxcinod significantly improves skeletal and cardiac disease phenotype in the mdx mouse model of dystrophy. Hum Mol Genet 23:3239-49
De Cock, Roosmarijn F W; Allegaert, Karel; Brussee, Janneke M et al. (2014) Simultaneous pharmacokinetic modeling of gentamicin, tobramycin and vancomycin clearance from neonates to adults: towards a semi-physiological function for maturation in glomerular filtration. Pharm Res 31:2643-54
Samiee-Zafarghandy, Samira; Smith, P Brian; van den Anker, Johannes N (2014) Safety of sildenafil in infants*. Pediatr Crit Care Med 15:362-8
Allegaert, Karel; van de Velde, Marc; van den Anker, John (2014) Neonatal clinical pharmacology. Paediatr Anaesth 24:30-8
Allegaert, Karel; van den Anker, John N (2014) The addition of tramadol to a standard i.v. acetaminophen/morphine analgesia protocol in neonates: purposeful or just polypharmacy? Paediatr Anaesth 24:1189-90
Wu, B; Cloer, C; Lu, P et al. (2014) Exon skipping restores dystrophin expression, but fails to prevent disease progression in later stage dystrophic dko mice. Gene Ther 21:785-93

Showing the most recent 10 out of 23 publications